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ABSTRACT

Radioactive microspheres for radiation synovectomy of
arithmetic joints in a mammal comprise a biodegradable
glass material and a beta radiation emitting radioisotope
chemically dissolved in and distributed substantially
uniformly throughout the glass material. The biode
gradable glass material may be lithium silicate, lithium
aluminosilicate, lithium aluminoborate, lithium germanate, lithium aluminogermanate, potassium silicate, po
tassium aluminosilicate, potassium, aluminoborate, po
tassium germanate or potassium aluminogermanate and
the beta radiation emitting radioisotope may be samari
um-153, holmium-166, erbium-169, dysprosium-165,
rhenium-186, rhenium-188 or yttrium-90. Methods for
preparing such microspheres and for carrying out radia
tion synovectomy of arthritic joints utilizing such mi
crospheres are also disclosed.
25 Claims, 2 Drawing Sheets
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loose and be painful, and (4) the fact that the implant
may break with unusual use.
COM POSm ON AND METHOD FOR RADIATION
Chemical and radioisotope synovectomy (synoviorSYNOVECTOMY OF ARTHRITIC JOINTS
thesis) constitutes an effective alternative to operative
5 therapy. The advantages of synoviorthesis are: (1) sim
BACKGROUND OF THE INVENTION
ple techniques employed in their use, (2) decreased or
This invention relates to radiation synovectomy for
no hospitalization, (3) lower costs, (4) early and easier
arthritic joints and, more particularly, to novel biode
mobilization of the patient, and (5) a surgical synovec
gradable and biologically compatible glass micro
tomy remains an alternative treatment should the
spheres or beads and their use in carrying out radiation
10 synoviorthesis not work.
synovectomy of arthritic joints.
In general, the results of radioisotope synoviorthesis
Current medical management of rheumatoid arthritis
appear to be superior to those attained with chemical
includes patient education, appropriate rest and physi
synovectomy. (Menkes, C. J., et al. La Synoviorthese a
cal therapy, and the use of anti-inflammatory drugs for
L’acide Osmique Chez L’hemophilie, Rev. Rhum.
relief of pain and inflammation. Ruddy, S., The Man
15 40:255, 1973; Oka, M., et al., The Fate and Distribution
agement of Rheumatoid Arthritis. Textbook of Rheu
of Intra-Articularly Injected Osmium Tetraoxide, Acta
matology, 2nd ed., W. B. Saunders Co. Philadelphia,
Rheum. Scand., 16:271, 1970; Delbarre, F., et al., La
1985, p. 979. Patients who do not respond to these mo
Synoviorthese par les Radio-Isotopes a la Main et au
dalities may require therapy with anti-malarial agents
Poignet, Rev. Rhum., 40:205, 1973). Some chemical
such as hydroxychloroquine (Bell, C. L., Hydroxychlo 20 agents that have been used are thio-tepa (Flatt, A. E.,
roquine Sulfate in Rheumatoid Arthritis: Long-Term
Intra-Articular Thio-Tepa in Rheumatoid Disease of
Response Rate and Predictive Parameters, American
the Hands, Rheumatism, 18:70, 1962; Feamley, M. D.,
Journal of Medicine, 75:46, 1983) or remission inducing
Intra-Articular Thio-Tepa Therapy in Rheumatoid Ar
agents including gold salts (Empire Rheumatism Coun
thritis, Aim. Phys. Med., 7:294,1963; Zuckner, J., et al.,
cil, Gold Therapy in Rheumatoid Arthritis: Final Re 25 Evaluation of Intra-Articular Thio-Tepa in Rheumatoid
port of a Multicentre Controlled Trial, Ann. Rheum.
Arthritis, Ann. Rheum. Dis., 25:178, 1966; Gross, D.,
Dis. 20:315, 1961), penicillamine (Multicentre Trial
Chemische Synovektomie mit Senfgas bei Primar ChroGroup: Controlled Trial of d(-) Penicillamine in Severe
nischer Polyarthritis, Z. Rheumforsch, 22:456, 1963;
Rheumatoid Arthritis, Lancet, 1:275, 1973), or azathioMondragon Kalb, M., Thiotepa en al Tratamiento de la
prine (Abel, T. et al., Long-Term Effects of Azathio- 30 Arthritis Rhumatoide, Medicina, 15:82, 1965), osmic
prine in Rheumatoid Arthritis, Arthritis Rheum. 21:539,
acid (Menkes, C. J., et al., La Synoviorthese a L’acide
1978). Despite the efficacy of these drugs, patient re
Osmique Chez L’hemophilie, Rev. Rhum., 40:255,1973;
sponse is variable and improvement may not occur until
Oka, M., et al., The Fate and Distribution of Intratreatment has extended for three to six months. When a
Articularly Injected Osmium Tetraoxide, Acta Rheum.
few joints remain swollen and painful and interfere with 35 Scand., 16:271, 1970; Von Reis, G., et al., Intra-Articuthe patient’s progress, intra-articular instillation o f corti
lar Injections of Osmic Acid in Painful Joint Affections,
costeroids may be used as an adjunct to systemic ther
Acta Med. Scand. Suppl., 259: 27, 1951; Berglof, F. E.,
apy. This local remedy, however, may be ineffective or
Further Studies on the Use of Osmic Acid in the Treat
may last only a few days (Owen, D. S., Aspiration and
ment of Arthritis, Acta Rheum. Scand., 10:92, 1964;
Injection of Joints and Soft Tissues, Textbook of Rheu 40 Martio, J., et al., Intra-Articular Osmic Acid in Juvenile
matology, supra, p. 546).
Rheumatoid Arthritis, Scand. J. Rheumatol, 1:5, 1972;
Surgery may be used in several different ways to help
Brattstrom, H., et al., Kombinierte Chemische und Op
the patient with rheumatoid arthritis. Surgery can help
erative Synovektomie es Kniegelenks, Orthapade, 2:73,
relieve pain, it can prevent further deformity and loss of
1973; Jakubowski, S., et al., Indikatronen zur Synovek
function, or at least allay these problems, and when 45 tomie bei pcP, orthopade, 2:6, 1973), varicoid (Tillman,
destruction has occurred, reconstructive procedures
K., Chemische Synovektomie, Orthopade, 2:10, 1973)
can return function to a part or a limb. Sledge, C. B.,
and gold (Delbarre, F., et al., supra). Radioactive sub
Introduction to the Surgical Management of Arthritis,
stances include Gold-198, Yttrium-90 citrate, YttriumTextbook of Rheumatology, supra, p. 1787.
90 resin, Rhenium-186, Erbium-169, Yttrium-90 ferric
Most of the operations done on rheumatoid patients 50 hydroxide, Radium-224 and Phosphorus-32 chromic
relieve pain. Fusions of joints, total joint replacement
phosphate (Sledge, C. B., supra).
and synovectomy are examples of procedures that sig
Beta-emitting radionuclides are considered the most
nificantly reduce pain. Conaty (Conaty, J. P., Surgery
useful for radiotherapeutic applications because of the
of the Hip and Knee in Patients with Rheumatoid Ar
moderate linear energy transfer (LET) of the ionizing
thritis, Journal of Bone and Joint Surgery, 55(A):301, 55 particle (electron) and its intermediate range (typically
1973) states that in rheumatoid arthritis, synovectomy
several millimeters in tissue). In contrast, gamma rays
was the most successful procedure for preserving mo
deliver dosage at lower levels over much greater dis
tion of a joint, except for total joint arthroplasty. This
tances, thus hampering the localization of the dose and
diluting its effect. Alpha particles represent the other
procedure, then, is preventive. Even so, eventually the
synovium regenerates and the process continues (Patza- 60 extreme; they deliver very high LET dosage, but have
an extremely limited range and must, therefore, be in
lds, M. J. et al., A Visual, Histological, and Enzymatic
intimate contact with the cells of the tissue to be treated.
Study of Regenerating Rheumatoid Synovium in the
In addition, alpha emitters are generally heavy metals,
Synovectomized Knee, Journal of Bone and Joint Sur
which limits the possible chemistry and presents undue
gery, 55(A):287, 1973). Total joint surgery will relieve
any or all of the aforementioned disabilities, but brings 65 hazards from leakage of radionuclide from the area to
be treated.
with it other problems that must be taken into consider
It is fortuitous that beta emitters, the most useful
ation by the surgeon. Some of these are: (1) cost, (2) the
radiotherapeutic radionuclides, are also the ones most
risk of infection, (3) the fact that the implants may come
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In our copending, coassigned application for U.S.
copiously produced by neutron capture in nuclear reac
patent Ser. No. 673,123, filed Nov. 19, 1984, now U.S.
tors, the most powerful sources of radioisotopes. Reac
Pat. No. 4,789,501, dated Dec. 6, 1988, we disclose
tor-produced isotopes number in the thousands, giving
novel microspheres for use in the radiation therapy of
researchers a wide choice of isotopes of various halflives, beta energies, gamma emissions, and chemical 5 liver cancer and other cancerous or tumor bearing tis
sue. Such microspheres have not, however, been used
properties. Gamma emissions, while not as useful for
or suggested for use in radiation synovectomy of ar
therapy as beta emissions, play an important role in that
thritic joints and may not be suitable for use in radiation
they permit the distribution of radioisotope in the body
synovectomy by reason of the radionuclides incorpoto be observed using an Anger gamma ray camera or
single photon computed tomography (SPECT) instru 10 rated therein having relatively long physical half-lives.
There is a continuing need, therefore, for improved
ment. This permits direct observation and, to some
microspheres and methods for radiation synovectomy
extent, quantification of radionuclide leakage from an
of arthritic joints.
organ or a joint and also provides positive verification
of the potency of joint injection and distribution of the
SUMMARY OF THE INVENTION
radionuclide in the research animal.
Among
the several objects of the invention may be
Treatment of the different depths of diseased syno
noted the provision of novel microspheres for use in
vium in joints of disparate size, such as the finger joints
radiation synovectomy of arthritic joints; the provision
and the knee, requires isotopes of different average beta
of such microspheres containing beta emitting radioisorange. It is important to achieve a “kill” of sufficient
depth to be efficacious without causing significant ne 20 topes which have a moderately abundant low energy
gamma photon that is in the energy range used for
crosis of overlying normal tissues.
nuclear medicine imaging; the provision of such microThe effectiveness of a radioisotope depends upon the
spheres which are biodegradable and advantageously
fact that it gives off beta radiation which kills tissue
gradually dissolve after they are no longer radioactive;
along with the .fact that it gives off no alpha and little
25 the provision of such microspheres which are prepared
gamma radiation. The latter type of radiation penetrates
in a nonradioactive form and may then be subjected to
too far, affecting tissues adversely, whereas beta radia
an effective amount of neutron irradiation to produce
tion has a short penetration distance, varying in millime
microspheres containing the desired beta emitting radi
ters for each radioisotope. Radioisotopes also have dif
oisotope; and the provision of methods for carrying out
ferent half-lives, some being far too long or too short for 30 radiation synovectomy of arthritic joints and for pre
any practical use. These factors, then, have to be con
paring biodegradable microspheres for use in radiation
sidered in the application o f a radioisotope for synoviorsynovectomy. Other objects and features will be in part
thesis.
apparent and in part pointed out hereinafter.
Sledge et al. (Treatment of Rheumatoid Synovitis of
Briefly, the present invention is directed to novel
the Knee with Intra-Articular Injection o f Dysprosium- 35 radioactive microspheres useful for radiation synovec
165 Ferric Hydroxide Macroaggregates, Arthritis and
tomy of arthritic joints. These radioactive microspheres
Rheumatism, 29(2):153, 1986) have used macroaggre
comprise a biodegradable or biologically compatible
gates of ferric hydroxide (FHMA) combined with dysglass material containing a beta radiation emitting radio
prosium-165. This compound does present the problem
isotope chemically dissolved therein. In a preferred
of some leakage to local lymph nodes and other tissues. 40 embodiment, such microspheres have been subjected to
Also, dyprosium-165 has a half-life of 2.3 hours, making
an acid wash to produce a sparingly soluble coating on
it necessary for the patient to be close to a nuclear reac
their outer surface so that the microspheres gradually
tor, severely limiting the use of this radioisotope. Even
dissolve after they are no longer radioactive.
with these drawbacks, the clinical results were note
Another aspect of the invention is the provision of
worthy, as 80% of patients treated for chronic synovitis 45 novel microspheres which are initially nonradioactive
of the knee with dysprosium-165-FHMA were im
and which, upon being subjected to an effective amount
proved at one year, and nearly 90% of patients with
of neutron irradiation, will produce a beta radiation
Stage 1 roentgenographic changes had excellent, good,
emitting radioisotope thereby rendering the micro
or fair results (Sledge, et al., Intra-Articular Radiation
spheres suitable for use in radiation synovectomy of
Synovectomy, Clinical Orthopaedics and Related Re- 50 arthritic joints while avoiding the handling of radioac
search, 182:37, 1984). These results and the results of
tive elements during initial production of the micro
others (Boerbooms, A. M., et al., Radio-Synovectomy
spheres.
in Chronic Synovitis of the Knee Joint in Patients with
A still further aspect of the invention resides in the
Rheumatoid Arthritis, European Journal of Nuclear
provisions of novel methods for carrying out radiation
Medicine, 10:446, 1985; Multicentre Trial Group: Intra- 55 synovectomy of arthritic joints utilizing the novel radi
Articular Radioactive Yttrium and Triamcinolone Hexoactive microspheres of the invention.
acetonide: An Inconclusive Trial, Ann. Rheum. Dis.,
BRIEF DESCRIPTION OF THE DRAWINGS
43:620, 1984; Kyle, V., et al., Yttrium-90 Therapy and
99mTc Pertechnetate Knee Uptake Measurements in the
FIGS. 1 and 2 are graphs showing the dissolution
Management of Rheumatoid Arthritis, Annals of the 60 (weight loss in mg/cm2) of two different glass composi
Rheumatic Diseases, 42:132, 1983; Rosenthall, L., Use
tions of the invention in deionized water at 37° C. as a
of Radiocolloids for Intra-Articular Therapy for Syno
function of time.
vitis, In Therapy in Nuclear Medicine, Grune and Strat
DESCRIPTION OF THE PREFERRED
ton, Inc., New York, 1978, p. 147; Spooren, P. et al.,
EMBODIMENTS
Synovectomy of the Knee with 90-Y, European Journal 65
of Nuclear Medicine, 10:441, 1985) show that radiation
In accordance with the present invention, it has now
synoviorthesis has a role in the treatment of inflamma
been found that certain novel radioactive microspheres
tory synovitis.
may be advantageously employed in radiation synovec-
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tomy of arthritic joints while substantially avoiding
systemic leakage of the beta radiation emitting radioiso
tope from the joint being treated and permitting greater
control of the particle size of such microspheres. The
radioactive microspheres of the invention are prepared 5
from novel microspheres which may be manufactured
and sized before radioactivity is induced providing the
advantage of working only with nonradioactive materi
als during initial production of the microspheres.
In a first embodiment of the invention, the novel 10
radioactive microspheres are comprised of a biodegrad
able glass material selected from the group consisting of
lithium silicate, lithium aluminosilicate, lithium
aluminoborate, lithium germanate and lithium aluminogermanate and containing a beta radiation emitting 15
radioisotope chemically dissolved in and distributed
substantially uniformly throughout the glass material,
the radioisotope being samarium-153, holmium-166,
erbium-169, dysprosium-165, rhenium-186, rhenium-188
or yttrium-90. It has been found that lithium silicate, 20
lithium aluminosilicate, lithium aluminoborate, lithium
germanate or lithium aluminogermanate biodegradable
glasses are particularly suitable for the purposes of the
invention since lithium does not become a gamma emit
ter upon being subjected to neutron irradiation whereas 25
sodium, calium and phosphorus, components of other
wise biodegradable glasses, do become gamma emitters
with unacceptably long half-lives upon neutron irradia
tion or become beta emitters which have undesirably
long half-lives or which bond to bone. For example, the 30
composition of the bioactive and partially biodegrad
able glass composition known as “Bioglass” is 45%
S i0 2, 24.5% Na20 , 24.5% CaO and 6% P20 5 (Hench,
Ceramic Implants for Humans, Advanced Ceramic
Materials, l(4):306-324, 1986), and this glass is unsuit 35
able because of the sodium, calcium and phosphorous it
contains.
Also, while use of the above-noted lithium glass ma
terials is preferred, potassium glasses selected from the
group consisting of potassium silicate, potassium alumi 40
nosilicate, potassium aluminoborate, potassium germa
nate and potassium aluminogermanate may also be used
in the practice of the invention. While potassium does
become a gamma emitter upon being subjected to neu
tron irradiation, the radioisotope potassium-42 thus 45
produced has an acceptably short half-life of approxiately 12 hours. Therefore, when such potassium glass
materials are employed, administration of the radioac
tive microspheres containing them is delayed for a suffi
cient time to permit the potassium-42 to decay to ac 50
ceptable levels.
The above-noted beta radiation emitting radioiso
topes are also particularly suitable for use in the present
invention. Samarium-153 (46.3 hr. half-life) and holmium-166 (26.8 hr. half-life) can readily be dissolved in 55
silicate, aluminosilicate or aluminoborate glasses, have
good activation properties in a nuclear reactor, possess
imageable gamma rays, exhibit low toxicity and have
half-lives long enough for distribution of the radioactive
60
microspheres of the invention containing them.
Holmium-166 is produced by neutron capture on
100% abundant, stable holmium-165 with thermal neu
tron and resonance neutron cross sections of 61.2 and
670 bams, respectively. It decays with a 26.83 hour
half-life by emission of 1.855 MeV (51%) and 1.776 65
MeV (48%) maximum energy beta particles with a
maximum range in water of about 8.0 mm and an aver
age range of about 2 mm. Since dysprosium-165 emits a
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beta particle of slightly lower maximum energy (1.31
MeV) and has proven efficacious in human knee radia
tion synovectomies, it appears that holmium-166 has
sufficient penetration for this application. Ho-166 also
emits an 80.5 KeV gamma-ray in 6.2% abundance and
thus is imageable by conventional techniques.
Samarium-153 is produced by neutron capture of
natural or isotopically enriched samarium-152 with
thermal and resonance neutron cross sections of 210 and
3,020 bams, respectively. It decays by beta emissions of
0.810 MeV (20%), 0.710 MeV (49%), and .640 MeV
(30%) maximum energies with concomitant ranges of
about 2.3 mm maximum and 0.8 mm average distance,
respectively. Sm-153 has a physical half-life of 46.27
hours and produces a highly imageable 103 KeV
gamma ray with an abundance of 29.8%, decaying to
stable Eu-153.
Samarium-153 and holmium-166 are both chemically
compatible and capable of being incorporated into
many types of glass in which no other significant radi
oactivities induced by neutron bombardment will be
present after about one day of decay. Erbium-169, dys
prosium-165, rhenium-186, rhenium-188 (from rhenium185 and rhenium-187) and yttrium-90 also possess the
desired properties rendering them suitable for use as the
radioisotope in this embodiment of the invention.
As mentioned, in the first embodiment of the inven
tion generally described above, a biodegradable glass
material is selected from the group consisting of lithium
silicate, lithium aluminoborate, lithium aluminosilicate,
lithium germanate and lithium aluminogermanate or the
corresponding potassium glass materials. Such glasses
may be doped with samarium oxide (Sm2C>3), holmium
oxide (Ho20 3) or oxide of erbium, dysprosium, rhenium
or yttrium in preparing the novel nonradioactive and
radioactive microspheres of the invention. By way of
example, such biodegradable glasses so doped may have
the following illustrative compositions by weight per
cent:
20.1% L2iO-74.9% S i0 2-5% Sm20 3
21.8% Li20-3.9% Al20 3-69.3% S i0 2-5% Sm20 3
19.7% Li20-13.1% B20 3-62.2% S i0 2-5% Sm20 3
It will be understood that other lithium silicate, lithium
aluminosilicate, lithium aluminoborate, lithium germa
nate and lithium aluminogermanate glass materials or
the corresponding potassium glass materials suitably
doped with samarium, holmium, erbium, dysprosium,
rhenium or yttrium may also be used in the practice of
the invention.
In a second embodiment of the invention, the novel
radioactive microspheres are comprised of a biologi
cally compatible glass material selected from the group
consisting of magnesium aluminosilicate and aluminosil
icate glass material and containing a beta radiation emit
ting radioisotope chemically dissolved in and distrib
uted substantially uniformly through the glass material,
the radioisotope being samarium-153, holmium-166,
erbium-169, dysprosium-165, rhenium-186 or rhenium188. While such glass materials are not biodegradable,
they are biologically compatible and are useful in the
practice of the invention. Such glass compositions may
be prepared by doping magnesium aluminosilicate or
aluminosilicate glass materials with oxides of samarium
(Sm20 3), holmium (Ho20 3), erbium (Er20 3), dyspro
sium (Dy20 3), or rhenium (R e02). Illustrative specific
examples of such glass compositions include the follow
ing compositions by weight percent.
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which catches the small glass beads or spheres as they
20% MgO-21% Al20 3-52% S i0 2-7% Sm20 3
are expelled from the flame.
40% Y2O3-20% Al2O3-40% S i0 2
After spheridization, the glass spheres are collected
40% Sm2O3-20% Al2O3-40% S i0 2
and rescreened with a sonic sifter. For use in the present
20% MgO-21% Al20 3-52% S i0 2-7% Ho20 3
invention, the fraction in the range of 3 to 30 microns in
20% MgO-21% Al20 3-52% S i0 2-7% R e0 2
diameter is recovered since this is the desirable size for
It will be understood that other magnesium aluminosili
use in radiation synovectomy of arthritic joints. After
cate or aluminosilicate glass materials suitably doped
screening, the microspheres in this size range are exam
with samarium, holmium, erbium, dysprosium or rhe
ined with an optical microscope and are then washed
nium may also be used in the practice of the invention.
The microspheres of the present invention may be 10 with a weak acid (HC1, for example), filtered and
washed several times with reagent grade acetone. The
prepared from a homogeneous mixture o f powders (i.e.
washed beads or spheres are then heated in a furnace in
the batch) that is melted to form the desired glass com
air to 500°-600° C. for 2-6 hours to destroy any organic
position. The exact chemical compounds or raw materi
material therein.
als used for the batch is not critical so long as they
The final step is to examine a representative sample of
provide the necessary oxides in the correct proportion 15
the microspheres in the selected size range or fraction in
for the melt composition being prepared. For example,
a scanning electron microscope. The size, range and
if a samarium doped lithium silicate glass is being made,
shape of the beads or spheres are evaluated, and the
then Sm20 3t Li2C 0 3 and S i0 2 powders would be used
quantity of undersize beads (less than 3 microns in diam
as the batch raw materials. The purity of each raw
20 eter) is determined along with the concentration of
material is typically greater than 99.9%. After either
non-spherical particles. The composition of the beads
dry or wet mixing of the powders to achieve a homoge
can be checked by energy dispersive x-ray analysis to
nous mixture, the mixture may be placed in a platinum
confirm that the composition is correct and that there is
crucible for melting. High purity alumina crucibles can
also be used if at least small amounts of alumina can be 25 an absence of chemical contamination.
The glass microspheres are then ready for activation
tolerated in the glass being made. The raw materials
by being subjected to an effective amount of neutron
must not contain impurities that become radioactive
irradiation which will produce a beta radiation emitting
from neutron irradiation.
radioisotope of samarium-153, holmium-166, erbiumThe crucibles containing the powdered batch are
then placed in an electric furnace heated to 1500° to 30 169, dysprosium-165, rhenium-186, rhenium-188 or yt
trium-90, the amount depending upon the particular
1600° C. depending upon the composition. In this tem
isotope of these elements that has been chemically dis
perature range, the batch melts to form a liquid which is
solved and uniformly distributed throughout the glass
stirred several times to improve its chemical homogene
material. The resulting radioactive microspheres of the
ity. The melt should remain at 1500° to 1600° C. until all
the solid batch is totally dissolved. This usually requires 35 invention have beta radiation emitting energies highly
suitable for radiation synovectomy of arthritic joints
2 to 5 hours duration. When melting and stirring is
and also provide gamma ray emissions suitable for nu
complete, the crucible is removed from the furnace and
clear medicine imaging devices.
the melt is quickly quenched to a glass by pouring the
In accordance with the invention, the radioactive
melt onto a cold steel plate or into cold clean water.
This procedure breaks the glass into fragments, which 40 microspheres prepared as described may be adminis
tered to the afflicted joints by intra-articular injection or
aids and simplifies crushing the glass to a fine powder
by other suitable means of administration. The micro
(less than 400 mesh). The powder is then sized and
spheres are believed to be chemically durable in joint
spheridized for use.
fluids and mechanically contained within the joint cav
The quenched and broken glass is first crushed to
about minus 100 mesh particle size using a mortar and 45 ity. Moreover, upon administration, they become dis
tributed reasonably uniformly along the synovial mem
pestle. The minus 100 mesh material, is then ground
brane and emit beta radiation of sufficient range to fully
using a mechanized mortar and pestle or ball mill until
or substantially fully irradiate the thickness of the mem
it passes a 400 mesh sieve. The minus 400 mesh particles
brane without giving significant dosage to more distant
(37 microns in diameter) may be stored in a dry con
tainer until used.
50 joint structures. Also, inasmuch as the thickness of the
diseased membrane varies in different joints, the present
The particles are formed into glass microbeads or
invention makes possible the preparation of micromicrospheres by introducing the minus 400 mesh parti
spheres doped with a different energy beta emitter for a
cles into a gas/oxygen flame where they are melted and
finger joint than for a knee, for example.
a spherical liquid droplet is formed by surface tension.
Further, the present invention provides smooth mi
This droplet is rapidly cooled before it touches any 55
crospheres which constitute a preferred shape over
solid object so that its spherical shape is retained in the
irregular, jagged particles with sharp edges and comers
solid. Just prior to spheridizing, the minus 400 mesh
for the purpose of radiation synovectomy of arthritic
powder is rescreened through a 400 mesh sieve to de
joints. The smooth surface of a sphere should be more
stroy any large agglomerates that may have formed
during storage. The minus 400 mesh powder is then 60 tissue compatible and less irritating than other shapes.
The smooth shape of the microspheres of the invention
placed in a vibratory feeder located above the gas/oxy
should also cause less friction, mechanical wear and
gen burner. The powder is slowly vibrated into a verti
inflammation in a joint with moving parts than irregu
cal glass tube which guides the powder particles di
larly shaped particles. Heretofore, radioactive microrectly into the hot flame of the gas/oxygen burner. A
typical rate for feeding the powder to the flame is 5 to 65 spheres of the type provided by the present invention
have not been available nor have glass microspheres of
25 grams/hour with the described apparatus. The flame
this type been injected into arthritic joints of humans or
of the burner is directed into a small metal container
animals.
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While, as indicated, the microspheres of the present
3-20% Al2O3-40% SiCh- The injections were made in
invention may be of various sizes, it is preferred for
the left stifles (knee) using Angiovist 370 contrast me
radiation synovectomy of arthritic joints that the microdium (diatrizoate meglumine and diatrizoate sodium;
spheres have a diameter within the range of about 3 to
Berlex Laboratories, Incorporated) as a suspending
30 micrometers (microns).
5 medium, with a control injection of Angiovist in the
To localize the desired radiation to the affected joint,
right stifle. The rabbits showed no ill effects whatsoever
the radioactive element is chemically dissolved in a host
over periods ranging from 48 hours to three months.
glass material which is insoluble in the body. The es
Upon sacrifice at intervals of 2 to 90 days, the stifles
cape or leakage of the radioactive material from the
were all dissected and slides prepared of various joint
joint has been a major problem with other types- of 10 tissues. Examination of the slides revealed microspheres
materials (e.g. colloids) previously used in this type of
only along the synovium with no spheres apparent in
radiation therapy and an insoluble glass should prevent
the underlying fat tissue or lymph nodes, and no me
any leakage since the radioactive material cannot es
chanical abrasion or damage to the cartilage or other
cape from insoluble glass microspheres. Also, for use in
joint structures.
human joints, there is a perceived advantage to using 15
EXAMPLE 2
glass beads or microspheres which gradually dissolve
after they are no longer radioactive, i.e. which are bio
FIGS. 1 and 2 show the dissolution (weight loss in
degradable. Accordingly, in accordance with the pres
mg/cm2) of two different glass compositions as shown
ent invention, it is preferred to employ the biodegrad
thereon in deionized water at 37° C. as a function of
able glass microspheres which are initially insoluble 20 time. The straight lines labeled 3 mos. and 6 mos. desig
during the period of time the bead is radioactive (i.e.
nate the dissolution needed for a 30 micron bead or
few weeks) and which then gradually starts to dissolve
sphere to dissolve in 3 and 6 months, respectively. In
and eventually disappear.
addition to untreated specimens (control), each figure
Biodegradable glass microspheres having such de
also shows the dissolution of specimens of each glass
sired characteristics may be prepared through another 25 composition washed in 1 N HC1 for 4 hours at either 25°
aspect of the present invention by treating the aboveor 50° C.
described biodegradable lithium silicate, lithium alumi
The effectiveness of the acid wash in reducing the
nosilicate, lithium aluminoborate, lithium germanate,
dissolution at short times is clearly evident in FIG. 1 for
lithium aluminogermanate or corresponding potassium
the specimen washed in HC1 at 25° C. In contrast to the
glass microspheres in such a way as to form an insoluble 30 unwashed control which showed an immediate weight
or sparingly soluble coating on its outer surface. This
loss, the sample washed in acid at 25° C. did not show
can be done by washing such glasses in common acids
any detectable weight loss for more than one week in
such as hydrochloric acid, nitric acid or sulfuric acid
deionized water. After about one week, the sample then
and thereby replace the lithium or potassium ions on the
began to dissolve as desired. Similar results are given in
outer surface with protons or H3O+. The results of this 35 FIG. 2, except that acid washing at 50° C. was more
dealkalization process is to produce a thin layer (skin)
effective for this glass because of its different composi
on the surface of the glass beads or microspheres whose
tion.
solubility is less than than of the underlying glass. A
These studies show that acid washing produces an
glass bead with such a dealkalized surface initially dis
insoluble surface skin which yields the dissolution char
solves slowly until the more durable outer surface layer 40 acteristics needed for radioactive, biodegradable glass
is dissolved, and then starts to dissolve faster as the less
microspheres for use in human joints.
durable, underlying glass is exposed to the surrounding
media.
EXAMPLE 3
Thus, washing glass microspheres o f the invention in
A. SAMPLE PREPARATION
common acids is an exemplary and practical means of 45
The glass compositions in the following table were
achieving the desired dissolution characteristics re
prepared from reagent grade chemicals. Batches yield
quired for radioactive, biodegradable glass micro
ing 50 grams of glass were melted in platinum crucibles
spheres for use in human joints. It will be understood by
in an electric furnace at approximately 1350° C. The
those skilled in the art that various factors are important
to the dissolution characteristics of the dealkalized sur- 50 melt was held at 1350° C. for 1 to 2 h for fining and
homogenization and then cast into steel molds to form
face or skin. These are: (1) the starting glass composi
bars measuring approximately 1X 1X 8 cm which were
tion, especially the amount of alkali ion (i.e. lithium or
annealed at 500° C. for 30 min. and then slowly cooled
potassium) present; (2) concentration and type of acid
to room temperature. Slabs approximately 0.2X1X1
employed; (3) temperature of the acid; (4) time of acid
treatment; and (5) heat treatment of dealkalized surface 55 cm were cut from the bars and ground to rectangular
shape using 180 grit silicon carbide paper.
after acid .wash. It will also be understood by those
skilled in the art that in addition to acid washing, other
procedures such as heating a glass in various gases such
C O M P O S IT IO N O F G L A S S E S
as SO2 and F2 can be used to produce a more chemically
B atch C om p osition (W eigh t % )
durable dealkalized skin on the lithium and potassium 60
G lass
u 2o
AI2O3
s m 2o 3
S1O2
glasses described above.
LSI
74.9
20.1
0.0
5.0
The following examples further illustrate the inven
LS3
69.3
21.8
5.0
3.9
tion.
EXAMPLE 1
31 rabbits were injected with about 5 mg each of
non-radioactive glass microspheres (20-30 microns in
size) having the composition by weight: 40% Y2O-

A portion of the LSI glass was broken and ground to
—200 mesh and wet milled for 6 h with methanol. The
powder was then dried and screened through a 325
mesh sieve. The —325 mesh glass powder was slowly

11
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treatments. The surface of slabs of each glass was pol
ished to 1 micron using silicon carbide polishing paper
and finally one micron AI2O3. These slabs were left
B. SURFACE TREATMENTS
untreated, treated in acid, or treated in acid followed by
1. Sulfur Dioxide Gas
5 heat treatment (LSI: 350° C. for 30 minutes, LS3: 400°
C. for 45 minutes). These samples were examined by
The glass slabs were placed in a tube furnace at either
SEM to determine if there was any change in the sur
400° or 500° C. SO2 gas was bubbled through water at
face due to washing in acid or washing in acid followed
25° C. at an approximate rat of one bubble per second
by heat treatment.
before flowing through the furnace. The treatment
times were 90 min. at 400° C. and 15 or 45 min. at 500° 10
E. RESULTS A N D CONCLUSIONS
C. After removal from the furnace, the slabs were
LSI glass which contains 74.9% Si0 2, 20.1% Li2 0,
cooled, rinsed in distilled water to remove any lithium
and 5.0% Sm203 (weight %) is well suited for micro
sulphate formed on the surface, and dried in an oven at
spheres that could be irradiated to treat rheumatoid
100° C.
15 arthritis. Acid washing followed by heating LSI re
2. Washing in HC1
duced the dissolution to zero. Glasses acid washed and
The glass was placed in a 0. IN HC1 solution in a
heated at 400° C. remained insoluble after 6 months.
beaker, magnetically stirred, rinsed in distilled water,
LSI glass acid washed then heated for 10 min. at 350° C.
and dried in air at 100° C. Initially, the effect of acid
remained insoluble for 4 weeks and then began to dis
washing on the glasses for 2,4, 6 or 8 h at 25° C., 50° C., 20 solve at approximately half of the rate calculated for a
or 75° C. was examined. The time and temperature
30 micron sphere to dissolve in 6 months. If this glass
which gave the longest delay before dissolution com
continued to dissolve at this rate, then a 30 micron
menced for LSI was 4 h at 25° C. an for LS3 was 4 h at
sphere treated in this way should be totally dissolved in
50° C. These times and temperatures were used in subse
12 months. Acid washing followed by heat tretment of
quent heat treatments.
25 LSI glass for 10 min. for 350° C. appears to create a
temporarily insoluble surface layer which should pre
3. Washing in HC1 Followed by Heat Treatment
vent the release of radioactive Sm-153.
After washing in 0.1 N HC1 acid, the glass slabs were
SEM photographs of polished LS3 glass shows that
heated on a steel plate in a furnace to 350° or 400° C. At
acid washing followed by heating causes the surface to
350° C., the slabs were heated for 10 or 30 min. and at 30 crack. This is probably due to a difference in thermal
400° C., the slabs were heated for 10, 30, 45, 60, or 90
expansion between the bulk glass and the dealkalyzed
min. Microspheres of LSI were heated at 350° C. for 30
layer. Acid washed then heated LS3 glasses began to
dissolve immediately confirming no protective layer
C. CHEMICAL DISSOLUTION
35 was created. In LS3 glass acid washed then heated at
400° C., the initial dissolution rate paralleled the acid
MEASUREMENTS
washed glass. After a few weeks, the dissolution de
After surface treatments, the glass slabs were
creased to almost zero, suggesting the corrosion process
weighed and their exact dimensions measured before
caused a protective layer to develop.
placing them in polyethylene bottles containing 125 mL
Washing LSI and LS3 glass in 0.1N HC1 delays the
of distilled water (pH=7). The bottles were placed in 40
dissolution of LS3 for 5 days and of LSI for 7 days.
an oven at 37° C., which is the temperature of the
Dissolution then begins at approximately the same rate
human body. The weight change of each slab was mea
as the untreated glass.
sured periodically by removing the slab from the bottle,
Exposure to hot sulfur dioxide gas decreases the dis
drying it in an oven at 100° C., and weighing.
solution
of LSI glass in water at 37° C. but does not
The average dissolution, D, of each sample was cal- 45
significantly affect the dissolution of LS3. No delay in
culated from the equation
dissolution occurred for either glass. Decreasing the
temperature of the SO2 treatment may facilitate the
D = (W 0-W ) /A
dealkalyzing reactions of the SO2 and improve the
where W0 was the initial weight of the original slab, W 50 chemical durability of the surface.
SEM photographs confirm that the acid washed then
was the current weight of the slab, and A was the sur
heated slabs of LSI which had a zero dissolution rate
face area of the slab. The dissolution was plotted against
show no effect of corrosion, while the acid washed and
time.
untreated slabs showed cracking after two weeks in
Approximately 20 mg of microspheres made from the
LSI glass were placed in polyethylene bottles contain- 55 water.
ing 25 mL of distilled water and placed in an oven at 37°
EXAMPLE 4
C. The microspheres were removed after 3 weeks for
About 10 mg. of non-biodegradable glass micro
SEM analysis.
spheres (10-20 microns in size) having the composition
D. SEM ANALYSIS
60 by weight: 20% MgO-21% Al20 3-52% S i0 2-7%
Sm203, were irradiated 10 minutes in a neutron flux of
Selected microspheres and slabs were mounted on a
4E13/square cm /sec to make about 300 microcuries of
steel cylinder for SEM analysis. The slabs were broken
and one piece was mounted to observe the corroded
Sm-153. The microspheres were irradiated in sealed,
surface and the other to observe the fresh fracture sur
high density polyethylene vials having a volume of
face. The mounted slabs and microspheres were vapor 65 slightly more than 1 cc and drawn into 1 cc tuberculin
coated with palladium.
syringes using Angiovist contrast medium as a suspend
Because the as-cut slabs had a very rough surface,
ing agent and injected into the stifles of healthy rabbits.
polished slabs were used to see the effects of surface
Serial imaging was performed to ascertain leakage.
fed into an oxygen/propane flame where surface ten
sion caused the molten particles to become spheres.
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11. A method as set forth in claim 1 wherein said
Significant leakage was observed down the leg of the
microsphere has a diameter in the range of about 3 to
first four rabbits, but this appeared to occur due to
about 30 micrometers.
leakage out of the injection puncture and possible tear
12. A radioactive microsphere for radiation synovec
in the joint capsule. A fifth rabbit injected through the
cartilage in the front of the knee (i.e. through a thicker, 5 tomy of arthritic joints in a mammal comprising a bio
logically compatible glass material selected from the
self-sealing portion of the joint) exhibited no leakage.
group consisting of magnesium aluminosilicate and alu
In view of the above, it will be seen that the several
minosilicate and containing a beta radiation emitting
objects of the invention are achieved and other advanta
radioisotope chemically dissolved in and distributed
geous results attained.
substantially uniformly throughout said glass material
As various changes could be made in the above prod 10
and being selected from the group consisting of samari
ucts and methods without departing from the scope of
um-153, holmium-166, erbium-169, dysprosium-165,
the invention, it is intended that all matter contained in
rhenium-186 and rhenium-188.
the above description or shown in the accompanying
13. A radioactive microsphere as set forth in claim 12
drawings shall be interpreted as illustrative and not in a 15 wherein said glass material is magnesium aluminosili
limiting sense.
cate and said radioisotope is samarium-153.
What is claimed is:
14. A radioactive microsphere as set forth in claim 12
1. A method for carrying out radiation synovectomy
wherein said glass material is aluminosilicate and said
of arthritic joints which comprises administering to a
radioisotope is samarium-153.
mammal affected with an arthritic joint an effective 20
15. A radioactive microsphere as set forth in claim 12
amount of microspheres comprising a biologically com
wherein said glass material is magnesium aluminosili
patible material selected from the group consisting of
cate and said radioisotope is holmium-166.
aluminosilicate, magnesium aluminosilicate, lithium
16. A radioactive microsphere as set forth in claim 12
silicate, lithium aluminosilicate, lithium aluminoborate,
wherein said glass material is aluminosilicate and said
lithium germanate, lithium aluminogermanate, potas 25 radioisotope is holmium-166.
sium silicate, potassium aluminosilicate, potassium
17. A radioactive microsphere as set forth in claim 12
wherein said microsphere has a diameter in the range of
aluminoborate, potassium germanate and potassium
about 3 to about 30 micrometers.
aluminogermanate and containing a beta radiation emit
18. A radioactive microsphere for radiation synovec
ting radioisotope chemically dissolved in and distrib
uted substantially uniformly throughout said glass mate 30 tomy of arthritic joints in a mammal comprising a biode
gradable glass material selected from the group consist
rial and being selected from the group consisting of
ing of lithium silicate, lithium alumino-silicate, lithium
samarium-153, holmium-166, erbium-169, dysprosiumaluminoborate, lithium germanate and lithium alumino
165, rhenium-186, rhenium-188 and yttrium-90.
germanate and containing a beta radiation emitting
2. A method as set forth in claim 1 wherein said glass
material is lithium silicate and said radioisotope is 35 radioisotope chemically dissolved in and distributed
substantially uniformly throughout said glass material
samarium-153.
and being selected from the group consisting of samari
3. A method as set forth in claim 1 wherein said glass
um-153, holmium-166, erbium-169, dysprosium-165,
material is lithium aluminosilicate and said radioisotope
rhenium-186, rhenium-188 and yttrium-90.
is samarium-153.
19. A radioactive microsphere as set forth in claim 18
4. A method as set forth in claim 1 wherein said glass 40
wherein said glass material is lithium silicate and said
material is lithium aluminoborate and said radioisotope
radioisotope is samarium-153.
is samarium-153.
20. A radioactive microsphere as set forth in claim 18
5. A method as set forth in claim 1 wherein said glass
wherein said glass material is lithium aluminosilicate
aterial is lithium silicate and said radioisotope is holmi
45 and said radioisotope is samarium-153.
um-166.
21. A radioactive microsphere as set forth in claim 18
6. A method as set forth in claim 1 wherein said glass
wherein said glass material is lithium aluminoborate and
material is lithium aluminosilicate and said radioisotope
said radioisotope is samarium-153.
is holmium-166.
22. A radioactive microsphere as set forth in claim 18
7. A method as set forth in claim 1 wherein said glass 50 wherein said glass material is lithium silicate and said
material is lithium aluminoborate and said radioisotope
radioisotope is holmium-166.
is holmium-166.
23. A radioactive microsphere as set forth in claim 18
8. A method as set forth in claim 1 wherein said glass
wherein said glass material is lithium aluminosilicate
material is magnesium aluminosilicate and said radioiso
and said radioisotope is holmium-166.
tope is samarium-153.
24. A radioactive microsphere as set forth in claim 18
55
9. A method as set forth in claim 1 wherein said glass
wherein said glass material is lithium aluminoborate and
material is aluminosilicate and said radioisotope is
said radioisotope is holmium-166.
samarium-153.
25. A radioactive microsphere as set forth in claim 18
10. A method as set forth in claim 1 wherein said glass
wherein said microsphere has a diameter in the range of
material is aluminosilicate and said radioisotope is yttri 60 about 3 to about 30 micrometers.
* * * * *
um-90.
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